Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 10

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 10
---
 AER, -8.6% CER). The decrease was mainly due to lower expenses attributable to termination of development programs such as modakafusp alfa (TAK-573) and EXKIVITY (for non-small cell lung cancer) partially offset by the depreciation of the Japanese yen.

Amortization and Impairment Losses on Intangible Assets Associated with Products

Amortization and Impairment Losses on Intangible Assets Associated with Products were JPY 440.2 billion (JPY -66.8 billion and -13.2% AER, -17.9% CER). Amortization Expenses increased (JPY +24.0 billion) mainly due to the depreciation of the Japanese yen. Impairment Losses decreased (JPY -90.8 billion) primarily due to higher impairment losses recorded for the nine-month period ended December 31, 2023, including JPY 74.0 billion impairment charges for ALOFISEL (for complex Crohn's perianal fistulas) and JPY 28.5 billion for EXKIVITY (for non-small cell lung cancer). Impairment Losses recorded for the nine-month period ended December 31, 2024 include a full impairment of intangible assets for soticlestat (TAK-935) amounting to JPY 21.5 billion following the results of the phase 3 studies.

#### Other Operating Income
Other Operating Income was JPY 16.2 billion (JPY +5.5 billion and +50.7% AER, +43.5% CER). The increase was mainly due to a JPY 6.1 billion gain recognized on completion of the sale of TACHOSIL (fibrin sealant patch), including a related manufacturing facility, during the nine-month period ended December 31, 2024.

#### Other Operating Expenses
Other Operating Expenses were JPY 165.4 billion (JPY +19.8 billion and +13.6% AER, +8.4% CER). The increase was primarily due to an increase in restructuring expenses (JPY +47.3 billion) mainly due to the enterprise-wide efficiency program during the nine-month period ended December 31, 2024. This increase was partially offset by higher provisions for legal proceedings related to the supply agreement litigation of AbbVie, Inc. (AbbVie) during the nine-month period ended December 31, 202